Associate Professor of Medicine, Dana-Farber Cancer Institute
Oncology
Dr. David Frank, OD
|
|
Give Review
David Frank works in the field of Oncology. He graduated from Yale University School of Medicine. Yale University School of Medicine is a one of the best medicals schools. Yale University School of Medicine is ranked 7 in research and 57 in primary care medicine He received awards:"Fellow (FACP)". David Frank is a published doctor and has 50 publications published. The lastest was: 'Inhibiting STAT5 by the BET Bromodomain Inhibitor JQ1 Disrupts Human Dendritic Cell Maturation.'
Publications
- Inhibiting STAT5 by the BET Bromodomain Inhibitor JQ1 Disrupts Human Dendritic Cell Maturation.
- Targeting STAT5 in Hematologic Malignancies through Inhibition of the Bromodomain and Extra-Terminal (BET) Bromodomain Protein BRD2.
- The transcriptional modulator BCL6 as a molecular target for breast cancer therapy.
- Fold Change of Nuclear NF-κB Determines TNF-Induced Transcription in Single Cells.
- Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer.
- JAK2-STAT5 signaling: A novel mechanism of resistance to targeted PI3K/mTOR inhibition.
- Whole-exome sequencing identifies a recurrent NAB2-STAT6 fusion in solitary fibrous tumors.
- Screening approaches to generating STAT inhibitors: Allowing the hits to identify the targets.
- Targeting STATs for cancer therapy: "Undruggable" no more.
- The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.
- Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways.
- RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
- A Chemical Biology Approach to Developing STAT Inhibitors: Molecular Strategies for Accelerating Clinical Translation.
- The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24- stem cell-like breast cancer cells in human tumors.
- The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.
- STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers.
- STAT3 Inhibition by Microtubule-Targeted Drugs: Dual Molecular Effects of Chemotherapeutic Agents.
- Microtubule-targeted chemotherapeutic agents inhibit signal transducer and activator of transcription 3 (STAT3) signaling.
- Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.
- STAT6 in PMBL: pathogenic or passenger?
- Reciprocal effects of STAT5 and STAT3 in breast cancer.
- CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy.
- Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.
- Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness.
- STAT1 expression is not required for polyp formation in Min mice.
- Review: Prophylactic use of granulocyte colony-stimulating factor reduces febrile neutropenia and short-term mortality in cancer.
- Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy.
- A small-molecule enhancer of signal transducer and activator of transcription 1 transcriptional activity accentuates the antiproliferative effects of IFN-gamma in huma...
- Monocyte 15-lipoxygenase expression is regulated by a novel cytosolic signaling complex with protein kinase C delta and tyrosine-phosphorylated Stat3.
- Identification of human STAT5-dependent gene regulatory elements based on interspecies homology.
- Cyclin D1 overexpression and response to bortezomib treatment in a breast cancer model.
- IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo.
- Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar.
- Tyrosine phosphorylation is required for functional activation of disulfide-containing constitutively active STAT mutants.
- Signal transducer and activator of transcription 1 activation in endothelial cells is a negative regulator of angiogenesis.
- Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth fac...
- Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells.
- Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
- The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells.
- Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors.
- Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma.
- Isolation of unique STAT5 targets by chromatin immunoprecipitation-based gene identification.
- Genome-wide analysis of STAT target genes: elucidating the mechanism of STAT-mediated oncogenesis.
- STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1.
- Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo.
- Interleukin-13 induction of 15-lipoxygenase gene expression requires p38 mitogen-activated protein kinase-mediated serine 727 phosphorylation of Stat1 and Stat3.
- In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immu...
- STAT3 Activity and Function in Cancer: Modulation by STAT5 and miR-146b.
- STAT3 Induction of miR-146b Forms a Feedback Loop to Inhibit the NF-κB to IL-6 Signaling Axis and STAT3-Driven Cancer Phenotypes.
Doctors Specialties
- Optometry
- Oncology
Accepted Insurances
Awards
- Fellow (FACP)
Education
-
Yale-New Haven Hospital -
Yale University School of Medicine
Hospital
-
Massachusetts General Hospital -
Dana-Farber Cancer Institute -
Brigham and Women's Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1457328957 |
| Last Name Of The Provider | FRANK |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Sarah M. Emswiler, OD |
|
|
Dr. Theanchai Tanlamai, OD |
|
|
Dr. Elena Z. Biffi, OD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lotfi B. Merabet, PHD |
|
|
Dr. Elizabeth Brem, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew J. Aguirre, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard Calderon, OD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Catherine Johnson, OD |
|
|
Dr. Anna Maria Baglieri, OD |
|
|
Dr. Peter S. Hammerman, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Douglas A. Rubinson, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Mary T. Hettler-Young, OD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hongxia L. Chen, OD |